Teleflex Incorporated (TFX)

Teleflex's stock price declined in the past six months, reaching $132.35 as of October 23, 2025, a 43.83% decrease from the previous year. Q1 2025 revenues decreased by 5% year-over-year, with adjusted EPS also declining. Q2 2025 earnings per share surpassed analysts' estimates, with revenue exceeding expectations. The company announced a quarterly dividend of $0.34. Teleflex announced its intent to separate into two independent publicly traded companies, expected to be completed mid-2026. Teleflex entered into an agreement to acquire BIOTRONIK's Vascular Intervention business for approximately €760 million.

Teleflex's revenue is influenced by seasonal and operational impacts, including a decline from Q4 2024 to Q1 2025 due to factors like EMEA order softness. Medical device sales can be affected by budgeting cycles, holiday periods, and elective procedure scheduling, contributing to demand fluctuations.

Teleflex, Inc. is a global provider of medical technology products, focused on single-use medical devices within the medical device sector. Its products serve critical care, surgical, diagnostic, and therapeutic applications. Key products include vascular access devices, interventional urology solutions, anesthesia and respiratory care products, surgical instruments, interventional cardiology devices, and OEM services.

Teleflex has a global presence, operating in over 150 countries with more than 14,000 employees. Headquartered in Wayne, Pennsylvania, USA, its operational segments include the Americas, EMEA, Asia, and OEM. Manufacturing facilities are located in the Czech Republic, Malaysia, Mexico, and the United States.

Teleflex maintains a reputation as a leading medical technology company through innovation, data-driven decisions, and clinical trial participation. The company invests in research and development and expands its portfolio through acquisitions. No specific negative events significantly impacting Teleflex's brand reputation were prominently reported between October 2024 and October 2025, although a Q2 2023 ET Tube recall was noted with recovery in Q1 2024.

Teleflex Incorporated's ownership is primarily institutional, with approximately 64.33% to 86.7% held by institutional investors, 0.42% by insiders, and the remainder by public companies and individual investors. Major institutional owners include T. Rowe Price Investment Management, Inc., BlackRock, Inc., and Vanguard Group Inc.